Overview

• The ingestible capsule expands into a six-armed star in the stomach and remains for about a week before its arms break off and pass through the digestive tract
• In an open-label study of 83 patients at five U.S. sites, weekly dosing upheld risperidone concentrations within the therapeutic range over five consecutive weeks
• Symptom assessments using the Positive and Negative Syndrome Scale showed stable schizophrenia control throughout the trial period
• Reported side effects were mild and transient, primarily early acid reflux and constipation among a minority of participants
• Developed over a decade at MIT and advanced by Lyndra Therapeutics, the weekly-dose platform is being adapted for other medications as researchers prepare larger trials and an FDA application